D3 Technologies is now Renishaw Diagnostics
12 May 2010
D3 Technologies Ltd, a provider of trace level detection techniques based on the exploitation of Surface Enhanced Resonance Raman Scattering (SERRS) for molecular diagnostics and research applications, has changed its name to Renishaw Diagnostics Ltd.
David A. Burns (pictured), CEO, said “the change of name to Renishaw Diagnostics reflects the direct focus of the company to become the premier provider of automated multiplex diagnostic and clinical research systems. These patented technology based systems will enable our customers to carry out fast, reliable and simplified disease detection leading to improved patient care. This move demonstrates the outstanding commitment and belief of our parent company in our people, our strategy and our science, and brings the power of the Renishaw global enterprise to enable us to accelerate our development of these ground breaking products.“
Multiplex diagnostic platform
Renishaw’s chairman and chief executive, Sir David McMurtry, added, “We are in the process of doubling the footprint at Renishaw Diagnostics’ facilities in Glasgow and the team is recruiting a world-class commercial organisation that will enable us to take our diagnostics products directly to market. Development progress with our multiplex diagnostic platform has demonstrated our unique position in sensitivity, accuracy and speed compared to existing disease testing methods and has impressed our clinical partners.“
D3 Technologies was a Strathclyde University spin-out before being acquired by the Renishaw Group.
Contact Details and Archive...